No Tenant, Huge Losses: Inside Fermi’s 2025 Shareholder Letter
Fermi reported a $486.4M net loss and zero revenue in its first year. Still no signed tenant for Project Matador AI power campus. Stock drops sharply.
NOTRELOAD AI
Lilly Signs $2.75B AI Drug Deal with Hong Kong’s Insilico Medicine
Eli Lilly has signed a $2.75 billion deal with Hong Kong-listed AI biotech Insilico Medicine for a GLP-1 diabetes drug.
Wells Fargo Calls Boston Scientific’s WATCHMAN Trial “Good, Not Great”
Wells Fargo says Boston Scientific’s CHAMPION-AF trial met all endpoints for WATCHMAN FLX but calls results “good, not great” due to slightly higher stroke rate vs blood thinners.
Morgan Stanley Boosts Insmed on Strong Brinsupri Outlook
Morgan Stanley upgrades Insmed to Overweight and raises price target to $212.
Big Move in Autoimmune Space: Aurinia to Buy Kezar Life Sciences
Aurinia Pharmaceuticals has agreed to acquire Kezar Life Sciences for $6.955 in cash per share plus a Contingent Value Right (CVR).
Anthropic’s New AI Model Could Supercharge CrowdStrike’s Growth
Wolfe Research upgrades CrowdStrike to Outperform and sets a $450 price target.